343 related articles for article (PubMed ID: 22908173)
21. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
22. Synthetic pregnenolone derivatives as antiviral agents against acyclovir-resistant isolates of Herpes Simplex Virus Type 1.
Dávola ME; Mazaira GI; Galigniana MD; Alché LE; Ramírez JA; Barquero AA
Antiviral Res; 2015 Oct; 122():55-63. PubMed ID: 26259812
[TBL] [Abstract][Full Text] [Related]
23. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey.
Burrel S; Aime C; Hermet L; Ait-Arkoub Z; Agut H; Boutolleau D
Antiviral Res; 2013 Nov; 100(2):365-72. PubMed ID: 24075863
[TBL] [Abstract][Full Text] [Related]
24. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV
mBio; 2019 May; 10(3):. PubMed ID: 31088925
[TBL] [Abstract][Full Text] [Related]
25. Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice.
Bhutta MS; Shechter O; Gallo ES; Martin SD; Jones E; Doncel GF; Borenstein R
Viruses; 2021 Jan; 13(1):. PubMed ID: 33435520
[TBL] [Abstract][Full Text] [Related]
26. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication.
Tavis JE; Wang H; Tollefson AE; Ying B; Korom M; Cheng X; Cao F; Davis KL; Wold WS; Morrison LA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7451-61. PubMed ID: 25267681
[TBL] [Abstract][Full Text] [Related]
28. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
Bourinbaiar AS; Coleman CF
Arch Virol; 1997; 142(11):2225-35. PubMed ID: 9672588
[TBL] [Abstract][Full Text] [Related]
29. Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by Melissa officinalis extract.
Astani A; Navid MH; Schnitzler P
Phytother Res; 2014 Oct; 28(10):1547-52. PubMed ID: 24817544
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
31. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
32. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
33. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
34. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir.
Andersen JH; Jenssen H; Gutteberg TJ
Antiviral Res; 2003 May; 58(3):209-15. PubMed ID: 12767468
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Suzuki M; Okuda T; Shiraki K
Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous titration and phenotypic antiviral drug susceptibility testing for herpes simplex virus 1 and 2.
Tardif KD; Jorgensen S; Langer J; Prichard M; Schlaberg R
J Clin Virol; 2014 Nov; 61(3):382-6. PubMed ID: 25204613
[TBL] [Abstract][Full Text] [Related]
37. Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids.
Kesharwani A; Polachira SK; Nair R; Agarwal A; Mishra NN; Gupta SK
BMC Complement Altern Med; 2017 Feb; 17(1):110. PubMed ID: 28196487
[TBL] [Abstract][Full Text] [Related]
38. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
Standring-Cox R; Bacon TH; Howard BA
J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
[TBL] [Abstract][Full Text] [Related]
39. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.
van Velzen M; van de Vijver DA; van Loenen FB; Osterhaus AD; Remeijer L; Verjans GM
J Infect Dis; 2013 Nov; 208(9):1359-65. PubMed ID: 23901090
[TBL] [Abstract][Full Text] [Related]
40. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.
Frobert E; Burrel S; Ducastelle-Lepretre S; Billaud G; Ader F; Casalegno JS; Nave V; Boutolleau D; Michallet M; Lina B; Morfin F
Antiviral Res; 2014 Nov; 111():36-41. PubMed ID: 25218782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
